Impairment of Investment Securities and Other Assets Due to Impairment in the Value of Investees
First written in FY2024. 4 of 6 entries say "Materialised", first in FY2026-H1. Latest entry: FY2026.
TAUNS Laboratories moved to the "Worse" side of this theme in 2025, 3 years after the typical company in this theme (2022).
The whole theme swung hardest in 2017: 8 of 23 companies on the "Worse" side.
24 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「Impairment losses of ¥391.404 million were recognized on shares of affiliated companies and ¥31.458 million on investment securities.」
Following the ¥241 million valuation loss on shares of affiliated companies in the previous fiscal year, the company recognized total impairment losses of ¥422.862 million on shares of affiliated companies and investment securities in the current fiscal year. - FY2026-H1MaterialisedAnnual report
「We recorded a ¥241 million valuation loss on shares of an affiliate as an extraordinary loss.」
A decline in the value of shares of an affiliate actually occurred, resulting in a ¥241 million valuation loss recorded as an extraordinary loss. - FY2025WorsenedAnnual report
「Issues whose number of shares increased during the fiscal year: unlisted shares, 4. Total acquisition cost related to the increase in shares: ¥4,041.369 million. Purpose: business alliances.」
Acquisitions of unlisted shares for business alliances reached 4 issues and approximately ¥4.04 billion, increasing exposure to the risk of impairment of investment securities. No impairment loss on investment securities was recorded during the fiscal year. - FY2024First statedAnnual report
「If the net asset value of an investee declines due to deteriorating profitability or if its business plan falls substantially below expectations, impairment of investment securities, shares of affiliates, or bonds of affiliates could affect our performance.」
The investment committee and the Board of Directors assess the rationale, benefits, risks, and consistency with the cost of capital when reviewing acquisitions and continued ownership.